Drugs / MR1-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01009866 | Nov 2006 → Dec 2012 | supratentorial cancer | Darell D. Bigner, MD, PhD | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MR1-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01009866 ↗ |
| Modality | Protein / enzyme biologic | “a novel, tumor-specific immunotoxin, MR1-1” NCT01009866 ↗ |